NASDAQ: INMInmed Pharmaceuticals Inc Stock
$0.29-0.01 (-3.33%)
Updated Apr 19, 2024
INM Price
$0.29
Fair Value Price
N/A
Market Cap
$1.76M
52 Week Low
$0.26
52 Week High
$2.08
P/E
-0.23x
P/B
0.14x
P/S
0.61x
PEG
N/A
Dividend Yield
N/A
Revenue
$5.49M
Earnings
-$6.35M
Gross Margin
38.4%
Operating Margin
-115.69%
Profit Margin
-115.8%
Debt to Equity
0.19
Operating Cash Flow
-$6M
Beta
1.3
Next Earnings
May 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A
INM Overview
InMed Pharmaceuticals Incorporated develops cannabinoid-based therapies. Its pipeline includes INM-755, a cannabinol topical cream in a second Phase I clinical trial for the treatment of Epidermolysis Bullosa, INM-088, in preclinical studies for the treatment of glaucoma, and INM-405 for the treatment of pain. It is also developing IntegraSyn, an integrated biosynthesis-based manufacturing process for synthesizing pharmaceutical-grade cannabinoids. InMed Pharmaceuticals was incorporated in 1981 and is headquartered in Vancouver, British Columbia, Canada.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how INM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
INM is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
INM is good value based on its book value relative to its share price (0.14x), compared to the US Biotechnology industry average (5.74x)
P/B vs Industry Valuation
INM is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more INM due diligence checks available for Premium users.
Be the first to know about important INM news, forecast changes, insider trades & much more!
INM News
Valuation
INM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.23x
Industry
15.81x
Market
40.51x
INM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.14x
Industry
5.74x
INM is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
INM's financial health
Profit margin
Revenue
$1.2M
Net Income
-$1.5M
Profit Margin
-119.2%
INM's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
INM's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$15.3M
Liabilities
$2.5M
Debt to equity
0.19
INM's short-term assets ($11.81M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
INM's short-term assets ($11.81M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
INM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.8M
Investing
-$9.3k
Financing
$4.7M
INM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
INM vs Biotech Stocks
Inmed Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.